Ensysce Biosciences, Inc. (ENSC) - Long-Term Debt to Capital

Ensysce Biosciences (ENSC) is developing innovative analgesics that are difficult to misuse. The business growth potential is high due to patent ownership, which will ensure global revenue with low production costs. The company is currently in the R&D phase, meaning the operating leverage is 0.00, and the expansion of the drug portfolio is increasing testing expenses. The price history on the GURU.Markets chart is supplemented by data on recruiting leading biochemists to the team via an RSU system.

This indicator assesses the company's reliance on borrowed funds with maturities exceeding one year. By analyzing the long-term financial leverage ratio, an investor determines the stability of the capital structure. The metric is calculated as the ratio of total long-term loans to the company's total equity. A decrease in this value minimizes bankruptcy risks. For Ensysce Biosciences (ENSC), such stability is critical when financing the green modernization of plants and implementing closed-loop water systems.